Provider: ValuEngine, Inc.
Actelion Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Actelion Ltd Gets Go-Ahead To Continue New Drug Trial-Reuters
Reuters reported that Actelion Ltd should continue a late-stage study into a new heart and lung drug, independent monitors have recommended, with final results now expected by mid-2014, giving the biotech firm hope it has a further product in its pipeline. Actelion said in a statement the Independent Data Monitoring Committee had told the Company it had unanimously recommended the continuation of a late-stage study in selexipag with no modifications, adding final results should come next year. Selexipag is the third drug from Actelion to treat pulmonary arterial hypertension (PAH), a progressively worsening condition characterised by abnormally high blood pressure in the arteries of the lungs. The cause is unknown and the disease has no cure. Actelion noted that an earlier study had already showed selexipag produced a reduction in pulmonary vascular resistance, a symptom of PAH. It said the goal of the interim analysis was to decide whether the study should be continued based on the primary objective of demonstrating the benefits of the drug.
Latest Developments for Actelion Ltd
Latest Key Developments in Biotechnology
- Alkermes PLC announces new drug application for Aripiprazole Lauroxil
- ICON PLC raises FY 2014 EPS outlook; narrows FY 2014 revenue outlook to a range in line with analysts' estimates
- GW Pharmaceuticals Plc announces Epidiolex receives orphan designation from European Medicines Agency for the Treatment of Dravet Syndrome
- Proteon Therapeutics Inc announces pricing of Initial Public Offering
- Share this
- Digg this